Podcasts about Lung cancer

Mikayla Pittman, Manager of Nationwide Lung Cancer Screening for the American Lung Association, joins Lisa Dent to discuss the rise of lung cancer in those who have never smoked.

Program notes:0:47 Gun injuries and deer hunting season1:47 Other associated injuries2:47 Coincidence of hunting?3:48 Restrict hunting guns to that use4:10 Can we avoid surgery in some with cancer?5:10 Dostarlimab treatment6:10 Can help avoid surgery in few who have this mutation7:10 Look at specific pathways7:30 Lung cancer treatment8:32 71% responded9:12 Impact of Pepfar funding freeze10:12 Looked at waiver scenarios11:12 Decreased deaths and infection12:13 Takes time to resume13:06 End

Lorlatinib is reshaping first-line treatment for ALK-positive NSCLC—but its distinct side effect profile demands proactive, personalized management. In this episode,  Stefanie Houseknecht, PharmD, BCOP (Johns Hopkins Medicine) and Monica Chintapenta, PharmD, BCOP (Parkland Health)share how they're navigating real-world use of lorlatinib, from interpreting long-term data to counseling patients through CNS effects, weight gain, and metabolic challenges.Highlights:Why lorlatinib is gaining traction in first-line ALK+ NSCLCWhat the long-term CROWN data really means for patient outcomesHow to handle tricky side effects like cognitive changes, weight gain, and hyperlipidemiaReal-world tips for patient counseling and supporting adherenceThe importance of catching drug interactions and staying ahead on labsHow pharmacists are shaping care across the oncology teamBonus: Hear how our guests find balance beyond the clinic, whether in the garden or on the Boston marathon course. About Our Guests:Monica completed her Doctor of Pharmacy at Texas Tech University Health Sciences Center and went on to complete PGY-1 and PGY-2 residencies at Tufts Medical Center and Froedtert & the Medical College of Wisconsin, respectively. At Parkland, she supports outpatient hematology/oncology care and leads quality initiatives.   Stefanie earned her PharmD from the University of the Pacific, followed by PGY-1 and PGY-2 residencies at Palomar Medical Center and the University of California-San Diego. Her work focuses on thoracic malignancies, access to oral targeted therapies, and patient outcomes. She is active in the International Association for the Study of Lung Cancer and serves as a preceptor to pharmacy trainees across the Mid-Atlantic.  

Arthur Robin Williams is an associate professor of clinical psychiatry at Columbia University and a research scientist at the New York State Psychiatric Institute. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.R. Williams. Death and Taxes — Is Alcohol the Solution? N Engl J Med 2025;392:1665-1667.

In this episode, you'll hear about the latest developments in tailoring cancer treatments to individual patients using Precision Oncology.  Two thought leaders, Simone Ndujiuba, a Clinical Oncology Pharmacist at Prime Therapeutics, and Karan Cushman, Head of Brand Experience and host of The Precision Medicine Podcast for Trapelo Health, discuss real-world research that is paving the way for Prime and our partners to help providers reduce turnaround times so patients can start treatment as soon as possible.  Join your host Maryam Tabatabai as they dig into this evolving topic of precision oncology. www.primetherapeuitics.com ⁠Chapters⁠Defining precision medicine (08:50)Evaluating real-world operational process of biomarker testing (14:36)Turnaround times are crucial (17:40)A patients view into the importance of time (24:39)Technology and process aid in time and process (29:30)Helping bridge knowledge gaps for providers and payers (33:55) The focus is on Precision Oncology right now (37:00)Precision medicine in other disease categories (40:09)Future of precision oncology is bright (42:07) References Singh, B.P., et al. (2019). Molecular profiling (MP) for malignancies: Knowledge gaps and variable practice patterns among United States oncologists (Onc). American Society of Clinical Oncology. https://meetings. asco.org/abstracts-presentations/173392 Evangelist, M.C., et al. (2023). Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. Journal of Clinical Oncology, 41(Supplement 16). https://doi.org/10.1200/JCO.2023.41.16_suppl.9109. Ossowski, S., et al. (2022). Improving time to molecular testing results in patients with newly diagnosed, metastatic non-small cell lung cancer. Journal of Clinical Oncology, 18(11). https://doi.org/10.1200/OP.22.00260 Naithani N, Atal AT, Tilak TVSVGK, et al. Precision medicine: Uses and challenges. Med J Armed Forces India. 2021 Jul;77(3):258-265. doi: 10.1016/j.mjafi.2021.06.020.  Jørgensen JT. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. Oncologist. 2019 Jul;24(7):e432-e440. doi: 10.1634/theoncologist.2019-0054.  MedlinePlus. What is genetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/genetics/understanding/testing/genetictesting/. MedlinePlus. What is pharmacogenetic testing? Retrieved on April 21, 2025 from https://medlineplus.gov/lab-tests/pharmacogenetic-tests/#:~:text=Pharmacogenetics%20(also%20called%20pharmacogenomics)%20is,your%20height%20and%20eye%20color.  Riely GJ, Wood DE, Aisner DL, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: non-small cell lung cancer, V3.2005. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.  Benson AB, Venook AP, Adam M, et al. National Cancer Comprehensive Network (NCCN) clinical practice guidelines: colon cancer, V3.2025. Retrieved April 21, 2025 from https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Rosenberg PS, Miranda-Filho A. Cancer Incidence Trends in Successive Social Generations in the US. JAMA Netw Open. 2024 Jun 3;7(6):e2415731. doi: 10.1001/jamanetworkopen.2024.15731. PMID: 38857048; PMCID: PMC11165384. Smeltzer MP, Wynes MW, Lantuejoul S, et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol. 2020 Sep;15(9):1434-1448. doi: 10.1016/j.jtho.2020.05.002.The views and opinions expressed by the guest featured on this podcast are their own and do not necessarily reflect the official policy or position of Prime Therapeutics LLC, its hosts, or its affiliates. The guest's appearance on this podcast does not imply an endorsement of their views, products, or services by Prime Therapeutics LLC. All content provided is for informational purposes only and should not be construed as professional advice.

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40) Role of ADCs for Patients with ER-Positive mBC (35:09) T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20) Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20) NCPD information and select publications

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

Satish N. Nadig, MD, PhD, Chief of the Division of Abdominal Organ Transplant and Director of the Northwestern Medicine Comprehensive Transplant Center, joins John Williams to talk about performing the first double-lung and liver transplant for advanced lung cancer in the U.S. Dr. Nadig tells John about the procedure, how transplants are dependent on ‘man’s […]

In this special re-release of Hope With Answers, lung cancer advocate Jill Feldman tackles a challenge that most patients never see coming—stigma. Originally aired in January 2020, this candid and emotional episode sheds light on the damaging assumptions patients face and how words can wound, even when well-intentioned. From doctors and friends to complete strangers, the first question many patients hear is: “Did you smoke?” It's a question that implies blame—and lung cancer survivors like Jill Feldman have heard it far too often. In this episode, Jill teams up with journalist Steven Petrow to unpack the emotional toll of these encounters and offer advice on how to respond with grace and strength. You'll also hear from Dr. Alice Berger, a lung cancer researcher investigating why young, non-smoking women are increasingly being diagnosed with lung cancer. Her work helps shift public perception and challenges outdated assumptions about who gets lung cancer—and why. This episode explores: The real impact of stigma on lung cancer patients How language shapes the patient experience What not to say to someone with lung cancer How empathy and civility can reshape conversations Groundbreaking research on lung cancer in non-smokers Whether you're a patient, caregiver, or advocate, this episode will change the way you think—and talk—about lung cancer. Show Notes | Transcript | Watch Video  

Satish N. Nadig, MD, PhD, Chief of the Division of Abdominal Organ Transplant and Director of the Northwestern Medicine Comprehensive Transplant Center, joins John Williams to talk about performing the first double-lung and liver transplant for advanced lung cancer in the U.S. Dr. Nadig tells John about the procedure, how transplants are dependent on ‘man’s […]

Satish N. Nadig, MD, PhD, Chief of the Division of Abdominal Organ Transplant and Director of the Northwestern Medicine Comprehensive Transplant Center, joins John Williams to talk about performing the first double-lung and liver transplant for advanced lung cancer in the U.S. Dr. Nadig tells John about the procedure, how transplants are dependent on ‘man’s […]

In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai's innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Mario Castillo-Sang, the Surgical Director of Mitral Valve and Heart Failure Therapies at St. Elizabeth Healthcare, Edgewood, Kentucky, USA, about totally endoscopic cardiac surgery. Chapters 00:00 Intro 01:17 Minimal Access Bedside Cardiac 04:37 Lung Cancer, Histological Subtype 09:29 TAVR vs SAVR, AS & CAD 12:22 Biopros TVR Outcomes 15:48 Mitral Annular Disjunction, MVR 18:47 Ozaki Technique, AV Reconst 20:46 Redo LVOT Reconst for Endocarditis 22:33 Totally Endoscopic ASD Closure TVR 24:08 Dr. Castillo-Sang, MI Bedside Endoscopy 40:51 Closing They explore key highlights from Dr. Castillo-Sang's CTSNet series Endoscopic Cardiac Surgery Series: The Swiss Army Knife Approach, his journey in performing endoscopic surgeries, and how he learned the techniques. Dr. Castillo-Sang shares the advantages of endoscopic surgery, as well as tips and recommendations for those wanting to learn this approach. He emphasizes the importance of the instruments he has worked with, detailing how these have improved over time. Additionally, they explore Dr. Castillo-Sang's involvement with the Endoscopic Cardiac Surgeons Club, discussing how he got involved and providing details about the club's upcoming annual meeting.   Joel also highlights recent JANS articles on the estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time, transcatheter vs surgical aortic valve replacement in Medicare beneficiaries with aortic stenosis and coronary artery disease, long-term outcomes after bioprosthetic tricuspid valve replacement, and outcomes of patients with mitral annular disjunction undergoing mitral valve repair.  In addition, Joel explores aortic valve reconstruction using the Ozaki technique, redo LVOT reconstruction for endocarditis, and totally endoscopic ASD closure with tricuspid valve repair. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) Estimated Worldwide Variation and Trends in Incidence of Lung Cancer by Histological Subtype in 2022 and Over Time: A Population-Based Study  2.) Transcatheter vs Surgical Aortic Valve Replacement in Medicare Beneficiaries With Aortic Stenosis and Coronary Artery Disease  3.) Long-Term Outcomes After Bioprosthetic Tricuspid Valve Replacement: A Multicenter Study  4.) Outcomes of Patients With Mitral Annular Disjunction Undergoing Mitral Valve Repair  CTSNET Content Mentioned  1.) Aortic Valve Reconstruction—The Ozaki Technique  2.) Redo LVOT Reconstruction for Endocarditis  3.) Totally Endoscopic ASD Closure With Tricuspid Valve Repair  Other Items Mentioned  1.) Endoscopic Cardiac Surgery Series: The Swiss Army Knife Approach  2.) Endoscopic Cardiac Surgeons Club  3.) Mini Heart Valves   4.) Aortic Valve Replacement Series     5.) Career Center 6.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Join us for an insightful episode of the Oncology Brothers podcast as we dive into the fast-evolving landscape of HER2-positive non-small cell lung cancer (NSCLC). In this first part of the two-part series, Drs. Rahul and Rohit Gosain were joined by Dr. Devika Das, a thoracic medical oncologist, and Dr. Fernando Lopez-Rios, a pathologist, to discuss the critical importance of testing and identifying HER2 alterations in lung cancer patients. In this episode, we covered: •⁠  ⁠The significance of HER2 alterations in NSCLC and how they differ from breast and gastric cancers. •⁠  ⁠The complexities of biomarker testing, including NGS, IHC, and FISH amplification. •⁠  ⁠Patient characteristics and phenotypes associated with HER2-positive disease. •⁠  ⁠The current testing workflows in clinical practice and the role of liquid biopsies. •⁠  ⁠Insights into the treatment landscape for HER2-positive NSCLC, including recent FDA approvals and ongoing clinical trials. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the integration of precision medicine in lung cancer treatment. YouTube: https://youtu.be/gMi-sflQyQo Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for the next episode, where we will explore treatment options for HER2-positive non-small cell lung cancer in greater detail!

Dr. Lauren Parks Nicola, Chief Medical Officer at RevealDx, has extensive experience dealing with the challenges of accurately describing lung nodules and distinguishing between benign and malignant nodules based on visual inspection of CT scans. RevealDx software tool integrates into the radiologists' workflow and uses advanced algorithms and a large database of lung nodule data to provide a malignancy score for lung nodules. This technology can help reduce unnecessary follow-up scans and invasive procedures for patients with benign lung nodules while identifying high-risk ones requiring more aggressive investigation. Lauren explains, "Reveal's product is a software that characterizes lung nodules. So lung nodules, little blips on a lung that we find on a chest CT. And the thing is, they're very, very common. Lots of patients have them, they can turn out to be cancer, most of them aren't. But with the knowledge that we have right now, just as radiologists looking at those nodules, it's really hard to tell which ones are going to turn out to be cancerous and which ones aren't."  "The software tool characterizes which nodules are more likely to be malignant and might need faster diagnosis, more aggressive workup, biopsy, some interventions, things that can help us diagnose cancer earlier when it's easier, less expensive, and much better for the patient to treat versus the ones that don't need that kind of care. And for a lot of patients, that means not needing follow-up scans, not needing biopsies, and not needing invasive treatments to prevent something that would never have been a problem for them in the first place. So it is that added information, as well as added clinical information, gives us and the patients tools to better predict how these are going to behave." #RevealDx #RadiologyAI #MedicalImaging #Radiology #LungCancer #DigitalHealth #ArtificialIntelligence #AI #AIinHealthcare #MedicalAI  reveal-dx.com Download the transcript here

Dr. Lauren Parks Nicola, Chief Medical Officer at RevealDx, has extensive experience dealing with the challenges of accurately describing lung nodules and distinguishing between benign and malignant nodules based on visual inspection of CT scans. RevealDx software tool integrates into the radiologists' workflow and uses advanced algorithms and a large database of lung nodule data to provide a malignancy score for lung nodules. This technology can help reduce unnecessary follow-up scans and invasive procedures for patients with benign lung nodules while identifying high-risk ones requiring more aggressive investigation. Lauren explains, "Reveal's product is a software that characterizes lung nodules. So lung nodules, little blips on a lung that we find on a chest CT. And the thing is, they're very, very common. Lots of patients have them, they can turn out to be cancer, most of them aren't. But with the knowledge that we have right now, just as radiologists looking at those nodules, it's really hard to tell which ones are going to turn out to be cancerous and which ones aren't."  "The software tool characterizes which nodules are more likely to be malignant and might need faster diagnosis, more aggressive workup, biopsy, some interventions, things that can help us diagnose cancer earlier when it's easier, less expensive, and much better for the patient to treat versus the ones that don't need that kind of care. And for a lot of patients, that means not needing follow-up scans, not needing biopsies, and not needing invasive treatments to prevent something that would never have been a problem for them in the first place. So it is that added information, as well as added clinical information, gives us and the patients tools to better predict how these are going to behave." #RevealDx #RadiologyAI #MedicalImaging #Radiology #LungCancer #DigitalHealth #ArtificialIntelligence #AI #AIinHealthcare #MedicalAI  reveal-dx.com Listen to the podcast here

In this episode, host Jonathan Sackier speaks with Alexander Spira about cutting-edge advances in lung and colorectal cancer, including EGFR and KRAS-targeted therapies. They also discuss Spira's leadership in oncology research, his thoughts on the evolving ‘town-gown' dynamic in US medicine, and his hopes for the future of cancer care.  Timestamps:  00:00 – Introduction 01:50 – Most memorable family travel adventure 03:30 – What inspired you to go into oncology 05:49 – Three recent publications in lung cancer 07:02 – Real-world data on colorectal cancer 08:15 – Sex/gender differences in non-small cell lung cancer 11:53 – The science of KRAS mutations and drug development 15:07 – Accelerating diagnostics and access to therapies 17:13 – The ‘town-gown' debate in American healthcare 18:09- Three Wishes 

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Joshua Sabari, a thoracic medical oncologist from NYU, to discuss the latest findings from the European Lung Cancer Conference (ELCC) 2025. We dived into several key studies that are shaping the future of lung cancer treatment, including: • KEYNOTE-799: Exploring the combination of concurrent chemotherapy and radiation with the PD-1 inhibitor pembrolizumab for unresectable non-small cell lung cancer (NSCLC). • LAURA: The impact of osimertinib in patients with EGFR mutations post-chemoradiation therapy. • MARIPOSA: The promising results of amivantamab and lisertinib in the metastatic setting for EGFR-mutated NSCLC. • KRYSTAL-7: Investigating the use of KRAS G12C inhibitors in frontline therapy. Join us as we discuss the implications of these studies, the importance of next-generation sequencing (NGS), and how to manage side effects associated with these new therapies. YouTube: https://youtu.be/akoXXAUEl_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology! #Oncology #LungCancer #ELCC2025 #EGFR #KRAS #CancerResearch #Podcast

Oncology here & nowIn this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more.Join Us

Could it be the SHOTS?We are pummeled with headlines about the horrors of chronic disease and cancers in America. Thanks to the MSM and #MAHA propaganda we are conditioned to believe it's due environmental contamination, genetic disorders and/or super scary deadly airborne viruses, among other things.But what if it is all connected to a century of mass vaccination?According to researcher Judyth Vary Baker, the SV-40 contamination of polio shots in the 1950's has set in motion a devastating course of death and chronic disease in America and the cover up has been one of the most sophisticated mass propaganda operations ever witnessed.Her story of participation in the first gain of function research in New Orleans in 1963 is a fascinating peak into where it all started and is critical in understanding how to stop the lies and misinformation to protect ourselves and our families.Tune in LIVE ——> https://rumble.com/v6ryhpj-part-2-live-exclusive-with-judyth-vary-baker..htmlWatch LIVE TODAY and follow the SJ Show on Rumble HERE: https://rumble.com/c/TheShannonJoyShowStart COOKING with toxin free ceramic!! The 100% toxin free P600 sizzle set is 55% OFF for the SJ audience!! Go to https://www.chefsfoundry.com/joy today to claim the limited time discount!Shannon's Top Headlines April 10, 2025:The Media Playbook for Measles Looks a Lot Like Its COVID Playbook — This Time, Kids Are the Pawns: https://childrenshealthdefense.org/defender/mary-holland-media-playbook-measles-covid-children-pawns/PREP Act Immunity Debunked By Ed Berkovich: https://sashalatypova.substack.com/cp/160881332IVERMECTIN and FENBENDAZOLE TESTIMONIAL - 60s year old Nebraska woman with Stage 4 Lung Cancer was saved from Hospice after only 1 month: https://makismd.substack.com/p/ivermectin-and-fenbendazole-testimonial-9acWhat Happens After A Vaccine Injury? https://substack.com/home/post/p-159017762BREAKING NEWS: Japanese researchers discover COVID-19 mRNA Vaccine spike protein damages blood vessels for up to 17 months: https://makismd.substack.com/p/breaking-news-japanese-researchersSJ Show Notes:Please support Shannon's independent network with your donation HERE:https://www.paypal.com/donate/?hosted_button_id=MHSMPXEBSLVT6Support Our Sponsors:Please help us welcome an AMAZING new sponsor Blackout Coffee!! Here is a GREAT deal just for the Joy audience - 20% off your first order—just head to https://www.blackoutcoffee.com/?p=Y7GEtILQS and use code JOY at checkout.SJ Collagen SPECIAL DEAL!! Get your Native Path collagen 45% OFF with a stock up special for the SJ audience! www.getnativepathcollagen.com/joyBe ready before you need it! Stock up now and protect your family. Go to https://www.allfamilypharmacy.com/JOY and use code JOY10 for 10% off your order.Colonial Metals Group is the company Shannon trusts for all her metals purchases! Set up a SAFE & Secure IRA or 401k with a company who shares your values! Learn more HERE: https://colonialmetalsgroup.com/joyLightly prepped and READY to go. Always be prepared for ANY emergency with The Satellite Phone Store! Everything you need when the POWER goes OUT. Use the promo code JOY for 10% off your entire order TODAY! www.SAT123.com/JoyPlease consider Dom Pullano of PCM & Associates! He has been Shannon's advisor for over a decade and would love to help you grow!Call his toll free number today: 1-800-536-1368Or visit his website at https://www.pcmpullano.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this episode, we are joined by Dr Stephen Bradley, lead author of a new paper published in the BJGP looking at rates of CXR use in general practice and how this influences lung cancer stage at diagnosis and mortality. He discusses the findings of his research and how this might influence our practice. In other research, we look at a new paper in the BMJ on orthostatic HYPERtension - yes, you read that correctly - does treatment help, and does it really matter in the first place? And from the Lancet, research looking at the role of urodynamic studies in women with refractory overactive bladder - does it improve outcomes, or should it be stopped?ReferencesBMJ Orthostatic hypertension and BP treatmentBMJ OH editorialLancet Refractory overactive bladder & urodynamic studiesBJGP CXR in GP & lung cancer staging and mortalitywww.nbmedical.com/podcast

In a special episode of Lung Cancer Voices, Dr. Paul Wheatley-Price sits down with Laura Greer, Senior VP & National Lead, Health & Wellness at Hill+Knowlton, for a timely discussion on what political change — or uncertainty — could mean for health policy, research funding, and advocacy? They chat about how the shifting political landscapes may impact healthcare: ripple effects of tariffs and economic pressures on patient care, cuts to NIH/HHS in the U.S. and what they mean for Canadian research, and how charities like Lung Cancer Canada can keep advocating — no matter the political climate.

Nature writer Andrew Darby on what he learned from his rambles through the wilds of Tasmania, communing with the world's oldest surviving trees. In particular, his ‘buttock clenching' ascent up a 60-metre-tall eucalyptus known as The Vibe Tower.Nature writer, Andrew Darby spent more than 20 years as a Fairfax correspondent based in Tasmania.His stories involved the natural beauty of the bush, including visits to wild places and to the people who protect them, but it was deadline-driven and he couldn't spend the time he wanted to.In 2017 Andrew was diagnosed with stage four lung cancer.He underwent immunotherapy and was given a maximum 18-months to live. It has been eight years since he entered his “second life”.Andrew was determined to fully inhabit his beloved Tasmanian bush, so he went by himself to commune with ancient trees.These are some of the world's oldest surviving trees, like King's Lomatia; some of the biggest trees, like a 60-metre-tall eucalyptus known as The Vibe Tower; and Andrew's favourite, the dignified Pencil Pine.The Ancients: Discovering the world's oldest surviving trees in wild Tasmania is published by Allen & Unwin.This episode of Conversations touches on wild Tasmania, ancient trees, Pencil Pine, King's Lomatia, King Billy Pine, Giant Eucalyptus, Peter Dombrovskis photography, Walls of Jerusalem National Park, Pool of Siloam, epic hike, solo hike, stage four lung cancer, immunotherapy, second life and loving nature, hikes of Australia.

Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970–2022  Cancer Smoking prevalence peaked in the 50s and 60s but has declined following the US Surgeon General's report in 1964 on its health risk. As 85% of lung cancer is attributable to smoking, the authors evaluated this impact by assessing lung cancer deaths averted, and person-years of life (PYL) gained between 1970 and 2022 using cancer mortality data from the CDC. The authors estimated 3,856,240 lung cancer deaths were averted and 76,275,550 PYL were gained during the study period (average of 19.8 PYL gained per death averted). The deaths averted were higher in men (2,246,610), but average PYL gained per death averted was higher in women (22.4 years). Lung cancer deaths averted accounted for 51.4% of the estimated decrease in overall cancer deaths.  The findings highlight the importance of tobacco controls and interventions and need for ongoing efforts to decrease tobacco use.    Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Anxiety is the most common mental disorder in the United States – even more common than depression!!! And don't miss the following topics that Terry will also discuss on this show: Lung Cancer in “Never Smoked” People is Increasing Dry Eye Problems Spike in the Winter Stressed at Work? Try Red Ginseng! What's In Your Water? Test Your Knowledge: Health Trivia Questions Vitamin D and Dementia Prevention Effects of Long COVID on Exercise

Welcome back to this week's Friday Review where I can't wait to share with you the best of the week!     I'm looking forward to reviewing:     Puriya Skin Repair Foot Balm (product review) The Healthiest Toothpastes (product review) Lung Cancer & RX (research) Accurate Blood Pressure Reading (research)   For all the details tune into this week's Cabral Concept 3346 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3346 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Dr. Vamsi Velcheti and Dr. Charu Aggarwal discuss the evolution of ctDNA as a critical tool in precision oncology and its implications for lung cancer management, including its potential role in the early-stage setting. TRANSCRIPT Dr. Vamsi Velcheti: Hello. I am Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I am a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health.  The management of small cell lung cancer has rapidly evolved over the past few decades, and today, molecular testing and biomarker testing for lung cancer are absolutely critical in terms of designing treatment options for our patients with metastatic non-small cell lung cancer. Today, I'm delighted to be joined by Dr. Charu Aggarwal for a discussion on ctDNA (circulating tumor DNA) and the role of ctDNA in lung cancer management. Dr. Aggarwal is the Leslye Heisler Professor of Lung Cancer Excellence and section chief of thoracic and head and neck oncology at University of Pennsylvania Abramson Cancer Center.  You'll find our full disclosures in the transcript of that episode.  Dr. Agrawal, it's great to have you on the podcast today. Thank you for being here. Dr. Charu Aggarwal: Thank you for having me. Dr. Vamsi Velcheti: Let's start off with setting the stage for ctDNA technology. These technologies have rapidly evolved from experimental conceptual stage to essential clinical tools for day-to-day clinical practice. Could you briefly discuss how recent advancements in ctDNA technologies are shaping our approach to precision medicine, especially in lung cancer? Dr. Charu Aggarwal: Absolutely. And you know, I think we need to just level set a little bit. What exactly is circulating tumor DNA? This is a way to assess exactly that. Every tumor sheds little pieces of tumor-derived DNA into the bloodstream, and this occurs in a variety of solid tumors. But now we have the technology to be able to derive this DNA that's actually being shed from the tumor into the bloodstream, these minute fragments of DNA, take them out, amplify them and sequence them with a variety of different mechanisms. They can be DNA sequencing alone, they can be DNA and RNA sequencing, they can be whole transcriptome sequencing. The technology, as you rightly pointed out, Dr. Velcheti, has significantly improved from just being able to look at circulating tumor DNA to now being able to amplify it, sequence it, and use it to offer personalized therapy. I think lung cancer is definitely the poster child for such an approach as we have a lot of data that has shown clinical utility and validity of being able to use circulating tumor DNA next-generation gene sequencing to guide therapy. Dr. Vamsi Velcheti: There have been so many technological leaps. It's really impressive how far we've come to advance these sequencing platforms. Recent advances with AI and machine learning are also playing important roles in interpreting ctDNA data. How are these computational advances really enhancing clinical decision-making in day-to-day clinical practice? Dr. Charu Aggarwal: I think while we have firmly established the role of ctDNA in the management of patients with metastatic lung cancer, some of the approaches that you talked about are still experimental. So let me backtrack a little bit and set the stage for how we use ctDNA in clinical practice right now. I think most patients, when they come in with a new diagnosis of stage IV lung cancer, we want to test for biomarkers. And this should actually be the established standard. Now included in the NCCN guidelines and actually also international guidelines, is to consider using blood-based testing or plasma-based testing to look for biomarkers, not just tissue-based testing which had been our historical standard, but to use these plasma guided approaches to identify the seven to nine biomarkers that may be truly implicated in either first- or second-line therapy that are called as your immediately actionable mutations.  What you're talking about is AI computational methods. I think there's a lot of excitement about how we can use genomic signatures that are derived from either tissue or ctDNA-based biomarker testing, combine it with radiomic features, combine it with histologic features, look at H & E patterns, use AI algorithmic learning to be able to actually predict recurrence scores, or can we actually come up with predictive signatures that may be extremely helpful?  So, I think some of the techniques and technologies that you're talking about are incoming. They are provocative. I think they're very exciting, but very early. Dr. Vamsi Velcheti: I think it's really amazing how many advances we have with these platforms. You know, the challenge really is the significant gap in terms of uptake of molecular testing. Even today, in 2025, there are significant gaps in terms of all metastatic lung cancer patients being tested for all biomarkers.  So, why do you think there's such a challenge in testing patients with lung cancer? In most academic practices, we try to achieve 100% testing for all our patients, but we know from recent studies that that's not the case across the country. What do you think the gaps are? Dr. Charu Aggarwal: Biomarker testing is so essential, like you pointed out, for us to be able to guide the right therapy for our patients. And we see this in our practice every day as you and I see patients with lung cancer, that a large proportion of our patients either don't get tested or they start therapy before their test results come back. So, I think this is a real problem.  However, to add some optimism to this problem, I do think that we are making a move in the right direction. So, four or five years ago, there was a lot of data being presented at national meetings, including ones from the American Society of Clinical Oncology, where we saw that, nationally, the rates of biomarker testing were probably in the rate of 40 to 50%. However, now with the availability of both tissue and plasma, I do think that the rates of biomarker testing are increasing. And if you were to survey a sample or even perform retrospective data research, I believe that the number is closer to 70% of all patients with metastatic non-small cell lung cancer.  And you know, you asked why is it not 100%? I think there are many reasons. I think the number one reason is tissue availability. Many times, the biopsies are small, or the tumor is very necrotic. So, either the tissue quantity itself is small, or the tissue quantity is insufficient to perform gene sequencing. And that's exactly where plasma comes in. When you don't have tissue availability, we have shown, as have others, that you can use plasma effectively to increase the proportion of patients who are not only tested but also receive the right therapy. I think there are also other barriers, including inertia. You know, I think this is both patient and physician inertia, where patients want to get started quickly, they don't want to wait. Physicians are very busy and sometimes want to be able to deliver treatment as soon as possible. We have seen there are some institutional barriers. Not every institution has in-house gene sequencing testing. So how do you really operationalize, send out these tests in a fast, efficient manner so that you get results back? Is it a pathologist who sends out the test? Is it the medical oncologist? Is it the pulmonologist or the interventionalist? I think there is this need to develop reflex testing mechanisms which some institutions do really well and some don't. And then finally, there are financial implications as well. How do we do this in a most cost-efficient fashion?  So there are many barriers, but I'm happy to say that we are making a move in the right direction as we are understanding that it's important to do it, it's easy to do it maybe with a value add of plasma, and finally, as you said, you know, as these technologies become more available, they're actually getting more cost-effective. Dr. Vamsi Velcheti: Dr. Aggarwal, you've been at the cutting edge of these advanced platforms and testing. So, what do you do in UPenn? How do you handle all these barriers and what is your workflow for patients in University of Pennsylvania? Dr. Charu Aggarwal: One of the things that I mentioned to you was there may be institutional barriers when it comes to gene sequencing. So, we actually, several years ago now, instituted a very robust reflex testing paradigm where almost all of our patients, regardless of stage, with a non-squamous non-small cell lung cancer diagnosis, would automatically be reflexively sent to our molecular pathology lab where they would get gene sequencing both for the DNA as well as with an RNA fusion-based platform. And the reason we did this was because we wanted to expedite and reduce the turnaround time. We also wanted to ensure that we were not just doing DNA testing, which I think is really important for our listeners here. There are many fusions as well as certain skipping mutations like MET exon 14 that may be missed on DNA testing alone. So, it's really incredibly important to run both DNA and RNA samples.  So, we do this routinely, and based on our research and others, what we also do routinely is that we send concurrent tissue and liquid biopsies or plasma MGS testing upon initial diagnosis. For example, if a patient comes in with a diagnosis of stage IV non-small cell lung cancer, their tissue might already be at my molecular pathology lab based on the reflex mechanism that I just described to you. But upon their initial meeting with me, we will send off plasma. And I will tell you this, that Penn is not just one institution, right? We have a large network of sites. And as part of my research, one of the things that we wanted to do was implement wide scale means to improve biomarker testing. And we have done this with the use of technology like you mentioned, Dr. Velcheti: How can we actually use AI? How can we leverage our electronic medical record to identify these patients? So, we have a nudge-based mechanism which actually facilitates the pending of orders for biomarker testing for patients with new diagnosis of metastatic non-small cell lung cancer. And we are looking at our rates of biomarker testing but also rates of completion of biomarker testing before first-line therapy started. So many of our participating sites are clusters for our randomized control trial to increase molecular testing. And I'm really excited about the fact that we're able to implement it not just at our main satellite, downtown Penn Hospital, but also across our community. Dr. Vamsi Velcheti: I think that's great. Thank you so much for those insights, Dr. Aggarwal. I think it's so important because having the best technology is just not enough. I think implementation science is actually a real thing. And I think we need to all learn from each other, advance these things.  So, I want to ask you about the new emerging paradigm in terms of using ctDNA. Of course, in the metastatic setting, we've been using ctDNA for molecular profiling for a while now. But the recent data around monitoring early-stage disease, especially post-operative monitoring, is an exciting area. There are a lot of opportunities there. Could you please talk us through the emerging data in lung cancer and how do we incorporate ctDNA-based monitoring MRD or should we even do that right now? Is the data ripe enough for us to kind of deploy this in a clinical setting? Dr. Charu Aggarwal: I think using ctDNA in the early-stage setting is our next frontier in lung cancer. I think naturally we have been able to successfully deploy this in the stage 4 setting. It made a meaningful difference in the lives of our patients, and we are a little bit behind the A ball in terms of how MRD is used in lung cancer. Because, you know, colorectal cancer has already done large-randomized trials based on ctDNA and MRD. It's routinely used in hematological malignancy. So, it makes sense that we should start to use it.  However, when I say this, I say this with excitement, but also a little bit of gentle caution saying that we actually don't quite have the prospective randomized data just yet on how to deploy. Yes, intuitively we would say that if you detect ctDNA and MRD, that patient is at higher risk. So, we identify that, but we actually don't know what to do with the second part of that information once you identify a patient with high risk. Are there other techniques that we can then come in with or other drugs that we can come in with to modify that risk? And that's the thing that I think we don't have right now. The other thing that we don't have right now is the timing of the assay, when to use it. Is it to be tested in the pre-op setting? Is the post-op test the best timing, or is it monitoring and dynamics of ctDNA that are most important? And the third thing I will say in terms of precautionary cause is that we don't know which test just yet. There are actually a few commercially available tests out in the market right now. We know about them and I'm sure our community colleagues know about them. Some of them even have Medicare approval. However, many of these tests are currently tissue informed. We don't have tissue uninformed tests. And what does that mean? Tissue uninformed means that you actually take a piece of tumor tissue, you sequence that tumor and based on the gene profile of that tumor, you actually design a panel that can then be used to track the mutations in the blood-based pack. This requires, as the name implies, a tumor. So can this be used in the pre-op setting is a large question. Because coming back to the idea of tissue availability, you and I both know that when we get FNAS and we use it for PDL-1 testing and we use it for gene sequencing, there often isn't enough tissue left for us to then either do whole genome sequencing or even whole transcriptome sequencing, which may be required to build some of these assays.  I think the future lies in this idea of tumor uninformed assays because if we could go to a blood only or a plasma only approach using novel signatures like proteomics or methylation, I think that's where the future is. But we're still a little bit early in the discovery stages of those, as well as to come are the validation stages so that we can be confident that these blood-only assays may actually give us an answer.  So, with those three cautionary notes, I would say that optimism is still very high. I think ctDNA MRD is the right place to think about. We need to do this for our patients to better identify high-risk patients and to think about means to escalate treatment for them. Dr. Vamsi Velcheti: Yeah, I completely agree, and I think with all the changes and evolution of treatments in the management of early-stage lung cancer now with neoadjuvant and adjuvant, there's really a need for an escalation and de-escalation of therapies post-operatively. And I think it's a huge opportunity. I think we all could learn from our colorectal colleagues. I think they've done a really good job at actually doing prospective trials in this setting. I think we're kind of a little behind here.  Dr. Charu Aggarwal: I think in the metastatic setting there are ongoing trials to look at this exact question. How do you choose an appropriate first-line therapy, a monitor ctDNA at the six-week trial? It's being evaluated in a trial called the “Shedders” trial, where if patients are still ctDNA positive at six weeks, then you can escalate treatment because they haven't “cleared” their ctDNA. There has been a lot of research that has shown that lack of ctDNA clearance in the metastatic setting may be a poor prognostic factor. We and others have shown that if you do clear your ctDNA or if you have a reduction in ctDNA load overall, that that is directly related to both an improved progression-free survival and overall survival. This has been shown with both tissue informed and uninformed assays. So I think it's very clear that yes, you can track it. I think the question is: Can you apply that data to the early-stage setting? And that's an open research question. A lot of groups are looking at that and I think it's completely reasonable, especially to determine duration of therapy, to determine optimal timing, optimal timing of scans even. And I think these are just such interesting questions that will be answered in the future. Dr. Vamsi Velcheti: And also like a kind of early detection of resistance patterns that might inform early initiation of combination strategies. And I think it's a lot of opportunities I think yet to be explored. A lot of exciting things to come and I'm sure we'll kind of see more and more data in the next few years.  Dr. Aggarwal, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been a pleasure to have you on the podcast today. Hope to see you at ASCO. Dr. Charu Aggarwal: Thank you so much. This was great and I remain so excited by all of the possibilities to improve outcomes for our patients. Dr. Vamsi Velcheti: Thank you to all the listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:  Dr. Vamsidhar Velcheti  @VamsiVelcheti  @vamsivelcheti.bsky.social Dr. Charu Aggarwal @CharuAggarwalMD   Follow ASCO on social media:  @ASCO on X (formerly Twitter)  ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. Vamsidhar Velcheti:  Honoraria: Glavanize Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Takeda, Janssen Oncology, Picture Health, Regeneron Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline  Dr. Charu Aggarwal: Consulting or Advisory Role: AstraZeneca, Daiichi Sankyo/AstraZeneca, Regeneron/Sanofi, Pfizer, Boehringer Ingelheim, Takeda, Arcus Biosciences, Gilead Sciences, Novocure, Abbvie Speakers' Bureau: AstraZeneca (an immediate family member) Research Funding (Inst): Merck Sharp & Dohme, AstraZeneca/MedImmune, Daiichi Sankyo/AstraZeneca, Lilly@Loxo, Candel Therapeutics  

Drs. Sabari and Yu discuss the molecular landscape of HER2-mutant lung cancer, including its genomic characteristics, common co-mutations, and differences between HER2 mutations and HER2 amplification. This discussion also explores the prevalence and clinical patterns of HER2 mutations, their oncogenic mechanisms, their impact on tumor behavior and metastases, and potential environmental or genetic contributors to their development.

April 2, 2025 - The American Cancer Society-Cancer Action Network's Michael Davoli and Roswell Park's Dr. Mary Reid advocate for legislation preventing insurers from charging out-of-pocket costs for recommended lung cancer screenings.

Helena Yu, MD and Joshua Sabari, MD explore the importance of testing for HER2 alterations in lung cancer; how HER2 positivity influences clinical decision-making; and the key methods used for detection, including immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing. It also addresses challenges in standardizing HER2 testing, disparities in access to biomarker testing, and the evolving role of liquid biopsy compared to traditional tissue biopsy.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XTY865. CME/MOC credit will be available until March 20, 2026."Experts vs AI" ADC Challenge—Lung Cancer Edition: Interpreting the Evidence, Exploring Practicalities In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XTY865. CME/MOC credit will be available until March 20, 2026."Experts vs AI" ADC Challenge—Lung Cancer Edition: Interpreting the Evidence, Exploring Practicalities In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XTY865. CME/MOC credit will be available until March 20, 2026."Experts vs AI" ADC Challenge—Lung Cancer Edition: Interpreting the Evidence, Exploring Practicalities In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XTY865. CME/MOC credit will be available until March 20, 2026."Experts vs AI" ADC Challenge—Lung Cancer Edition: Interpreting the Evidence, Exploring Practicalities In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XTY865. CME/MOC credit will be available until March 20, 2026."Experts vs AI" ADC Challenge—Lung Cancer Edition: Interpreting the Evidence, Exploring Practicalities In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XTY865. CME/MOC credit will be available until March 20, 2026."Experts vs AI" ADC Challenge—Lung Cancer Edition: Interpreting the Evidence, Exploring Practicalities In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

In this deeply personal and eye-opening episode, Michaela shares the latest hopeful update on her mother's cancer journey — including how early research into ivermectin and fenbendazole is shaping their current protocol.You'll hear how these unconventional, off-patent medications are showing potential anticancer effects in lab studies, why they're gaining interest in holistic spaces.Michaela also explores the power of test-based nutrition, the importance of asking better questions, and why critical thinking might just be the most powerful supplement of all.BONUS! Methylated vitamin B YEY OR NAY? Listen in the first 5 min and you will find a surprise! 

Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignancies.

In episode 85 of the Summits Podcast, Vince Todd, Jr. is joined by Nate Spangle, Founder of Get Indiana and Head Wrestling Coach at Bishop Chatard High School. Tune in as Nate shares the family cancer story that set the trajectory for his young adulthood and inspired him to live bigger. The Heroes Foundation is thrilled to introduce Nate as the Honorary Chair and Accountability Coach for the 2025 Fit4Heroes campaign, Powered by American Health & Wellness, from April 1-30! Join Nate today at heroesfoundation.org/fit4heroes.

Did you know that lung neuroendocrine tumors (NETs) are often misdiagnosed as lung cancer due to overlapping imaging and histological features? Credit available for this activity expires: 3/18/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002284?ecd=bdc_podcast_libsyn_mscpedu

Host: Ece Cali Daylan, Assistant Professor of Medicine, Division of Oncology at Washington University School of Medicine Guest: Saadettin Kilickap Guest: Ozden Altundag

The Microbiome and Immunotherapy for Lung Cancer by IASLC

As part of IASLC's ongoing series of podcasts in world languages, Dr. Balazs Halmos moderates a discussion in Hungarian with Dr. Krisztina Bogos, Dr. Ferenc Rényi-Vámos and Dr. Zsolt Megyesfalvi. The podcast reviews recent advances in lung cancer screening, diagnosis and management with a particular focus on implementation in Hungary. Highlights of the discussion include novel staging and diagnostic tools, state-of-the-art biomarker testing, perioperative therapy and clinical trials access. Host: Balazs Halmos, MD, Director, Thoracic Oncology & Clinical Cancer Genomics, Montefiore Medical Park at Eastchester, Bronx, New York Guest: Ferenc Rényi-Vámos, MD, PhD, Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, Hungary Guest: Krisztina Bogos, MD, Thoracic Oncology National Koranyi Institute of Pulmonology, Budapest, Hungary Lung Cancer Research and Pathology Guest: Zsolt Megyesfalvi, MD, PhD, Semmelweis University and National Institute of Oncology, Budapest, Hungary and National Koranyi Institute of Pulmonology, Budapest, Hungary

Lung cancer is on the rise, even among those who have never smoked. Dr. Stephen Lam is a respirologist with the BC Cancer Research Centre, and has dedicated his career to lung cancer research and early detection. Stephen dives into the role of AI in predicting lung cancer risk and practical strategies to safeguard your lungs.

State of the Bay offers a compassionate look at homelessness with longtime San Francisco Chronicle journalist Kevin Fagan and examines Stanford Medicine's Dr. Bryant Lin's shift from researching lung cancer to confronting his own terminal diagnosis.

What if a cancer treatment worked—until it suddenly didn't? A new case report, “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report,” published in Oncotarget, reveals how a non-small cell lung cancer (NSCLC) patient developed drug resistance through a rare genetic alteration, allowing the cancer to evade therapy. This unexpected finding highlights the importance of advanced genetic testing and personalized cancer treatments. Non-Small Cell Lung Cancer, Targeted Therapy and Drug Resistance Non-Small Cell Lung Cancer is the most common type of lung cancer, accounting for nearly 85% of all cases. Some patients with NSCLC have genetic mutations, such as ROS1 gene fusions, that drive tumor growth. These patients often respond well to targeted therapies like lorlatinib, a ROS1 inhibitor that blocks cancer growth. However, cancer is constantly evolving. Over time, it can develop resistance to targeted therapies, leading to treatment failure. Understanding these resistance mechanisms is crucial for precision oncology, the approach of tailoring cancer treatment based on a patient's unique genetic profile. Full. blog - https://www.oncotarget.org/2025/03/12/a-rare-genetic-shift-that-helped-lung-cancer-evade-treatment/ DOI - https://doi.org/10.18632/oncotarget.28682 Correspondence to - Wade T. Iams - wade.t.iams@vumc.org Video short - https://www.youtube.com/watch?v=HE_qSkcRZho About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Drs Camidge and Nechtman discuss Nechtman's experience supporting and caring for his wife Laura during her lung cancer diagnosis and treatment; the emotional and practical challenges they faced as a family during her battle with cancer; and Nechtman's commitment to continuing Laura's patient advocacy work to advance lung cancer research. 

Fergal Bowers, Health Correspondent, reports that the first pilot screening programme of its kind for lung cancer has been announced for the communities of North Dublin and the North East, using mobile scanning units.

In this edition of Super Bowl HalfZeit Show, Jack and Miles discuss Kendrick's upcoming Super Bowl Halftime Show, Elon Musk's popularity dropping among republicans, Netanyahu and Trump exchanging gifts, lung cancer rates going up among non-smokers (more at 11!) and much more!See omnystudio.com/listener for privacy information.